This is an exploratory, single center, open label, prospective study of BR55 to determine the optimal phase of the menstrual cycle for performing BR55 contrast-enhanced ultrasonography (CEUS) of the target ovary in premenopausal women scheduled to undergo preventative surgery because of high familial/hereditary or genetic risk for ovarian cancer.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
3
BR55 will be administered at doses of 0.03 mL/kg or 0.05 mL/kg
Stanford University Medical Center
Palo Alto, California, United States
Adverse Events
Number of participants who received the contrast agent and experienced an adverse event.
Time frame: From the time of signing Informed Consent through 24 hours post-dose, up to a maximum of 11 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.